CD34+ Selected Cells For The Treatment Of Poor Graft Function Following Allogeneic Stem Cell Transplantation

• Published in: Blood 2013-11, Vol.122 (21), p.3306-3306
• Main Authors: Stasia, Alessandra, Ghiso, Anna, Raiola, Anna Maria, Galaverna, Federica, Varaldo, Riccardo, Gualandi, Francesca, Dominietto, Alida, Pozzi, Sarah, Luchetti, Silvia, Pogliani, Enrico Maria, Bacigalupo, Andrea
• Format: Article
• Language: English
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V122.21.3306.3306

We have previously defined poor graft function (PGF) as 2 or 3 cytopenic lines (Hb 100.000 x 109/L. A partial recovery was defined as transfusion independence, without a complete hematologic recovery. The median follow up was 1245 days. Tri-lineage recovery was seen in 31/41 (76%) and 3/43 patients became transfusion independent, for an overall response of 83%). The median time for complete hematological recovery from CD34+ boost infusion was 183 days. There was no influence on tri-lineage recovery of the following factors : dose of CD34 cells ( 3.3) (78% vs 72%), nor patient age (35 years) 75% vs 76%, nor donor type (HLA id sib 83%, UD 79%, family mm 68%). All the patients who achieved tri-lineage recovery are alive and disease free (28/41 patients). In this cohort 13 patients died due to relapse 9/14 (64%) or GVHD 2/14 (14%) or other causes 2/14 (14%). The overall actuarial survival is 63% with a median follow up of 1245 days (94-4151 days). We confirm that infusion of CD34+ selected PBSC is associated with a high rates of tri-lineage recovery, with low risk of acute or chronic GVHD in patients who develop poor graft function following an HSCT. Tri-lineage recovery or achieving transfusion independency have an interesting impact either on disease free and overall survival. ▪ No relevant conflicts of interest to declare.